<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Brownian motion: Personnel moves within the life sciences</title>
	<atom:link href="http://venturebeat.com/2007/06/01/brownian-motion-personnel-moves-within-the-life-sciences/feed/" rel="self" type="application/rss+xml" />
	<link>http://venturebeat.com/2007/06/01/brownian-motion-personnel-moves-within-the-life-sciences/</link>
	<description>News About Tech, Money and Innovation</description>
	<lastBuildDate>Mon, 23 Nov 2009 21:25:39 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: VentureBeat &#187; Life sciences briefing: Monday, Aug. 13, 2007</title>
		<link>http://venturebeat.com/2007/06/01/brownian-motion-personnel-moves-within-the-life-sciences/comment-page-1/#comment-423012</link>
		<dc:creator>VentureBeat &#187; Life sciences briefing: Monday, Aug. 13, 2007</dc:creator>
		<pubDate>Mon, 13 Aug 2007 21:43:34 +0000</pubDate>
		<guid isPermaLink="false">http://venturebeat.com/2007/06/01/brownian-motion-personnel-moves-within-the-life-sciences/#comment-423012</guid>
		<description>[...] Glide Pharma raises $4.6M for needle-free drugs &#8212; U.K. specialty pharma Glide Pharma raised $4.6 million (£2.3 million). Investors included Oxford Technology 4 VCT and Oxford Capital Partners. The company is developing drugs that can be delivered via its own needle-free injection system. We&#8217;ve written about other startups pursuing similar technology, including StrataGent Life Sciences and Macroflux. [...]</description>
		<content:encoded><![CDATA[<p>[...] Glide Pharma raises $4.6M for needle-free drugs &#8212; U.K. specialty pharma Glide Pharma raised $4.6 million (£2.3 million). Investors included Oxford Technology 4 VCT and Oxford Capital Partners. The company is developing drugs that can be delivered via its own needle-free injection system. We&#8217;ve written about other startups pursuing similar technology, including StrataGent Life Sciences and Macroflux. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
